2 results for "Buchholz".
#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)
Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: PD Dr. Patricia Grabowski
Introduction: Pancreatic neuroendocrine malignancy is rising up in the last decade. Despite surgical resection and palliative therapy, an effective therapy has not been developed yet.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Pietro Di Fazio